\ Pipeline
Advancing the future of HDAC6 therapeutics
The Augustine Therapeutics pipeline is based on a novel generation of small molecule inhibitors of HDAC6, a validated molecular target with strong biological rationale for neuromuscular and neurodegenerative disorders, and high therapeutic potential in other cardiometabolic, inflammatory and autoimmune diseases.
We currently have three programs in development.
AGT-100216
CMT
The first peripherally-restricted, selective HDAC6i for Charcot-Marie-Tooth disease (CMT), currently in a Phase 1 clinical study.
IND-ENABLING
Peripheral HDAC6i
Cardio-metabolic Disorders
2nd Gen peripherally-restricted HDAC6i for cardiometabolic diseases, currently inadvanced lead optimization.
Lead optimization
Central Acting HDAC6i
Neurodegeneration
A brain-penetrant HDAC6i for neurodegenerative diseases like ALS, currently in lead optimization.
Early discovery
Phase 1
Phase 2
Want to learn more about our programs?
Contact Us
Contact Us
